B-ALL is characterized by the expression of either strong CD19 and another strongly expressed B-lineage marker (i.e., CD79a, CD22, and CD10) or weak CD19 and two other strongly expressed B-lineage markers (14). This evidence concerns the gene MME and precursor B-cell acute lymphoblastic leukemia.